Loading stock data…
$34.02-0.24 (-0.70%)
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
IDEAYA Biosciences, Inc. in the Healthcare sector is trading at $34.02 with a market capitalization of $3.7B. Wall Street consensus targets $52.75 (12 analysts), implying a +55.1% move over the next 12 months. The stock is currently 20% below its 52-week high of $42.68, remaining 0.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $8.86M↑ | $6.56M↓ | $10.88M↓ | $207.83M | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$122.29M↓ | -$108.54M↓ | -$94.57M↓ | $108.45M↑ | -$88.81M |
| Net Income | -$112.45M↓ | -$98.54M↓ | -$83.27M↓ | $119.24M↑ | -$77.49M |
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein...